Efficacy: Success during initial treatment period

In addition to efficient administration, efficacy during the acute treatment phase is a critically important feature of a surfactant. Rapidly improved oxygenation, sustained efficacy, and fewer doses can all help wean infants to less invasive forms of ventilation.

Explore 3 features of CUROSURF efficacy that can help you experience fast RDS success1-3:

Rapid onset of action
Sustained results with fewer doses
Single-dose success in 73% of infants treated with CUROSURF2

Rapid onset of action

CUROSURF improves oxygenation within 5 minutes and rapidly reduces FiO2 requirements over the initial treatment period.1,2 It has been suggested that these results may allow you to wean infants off the ventilator sooner.2 As you can see below, infants treated with CUROSURF experienced faster FiO2 reduction than those treated with Survanta® over a 6-hour period.2

Physiological end points (eg, faster reduction in FiO2) have not been proven to impact key clinical outcomes such as mortality due to RDS.

Chart showing faster reduction in FiO2 vs Survanta
Rapid reduction of FiO2 levels may help you wean infants off the ventilator sooner.2

Adapted from Ramanathan R, et al. Am J Perinatol. 2004. (N=293)

Sustained results with fewer doses

In addition to a rapid onset of action, CUROSURF demonstrates sustained clinical results through the first 48 hours. In a clinical study, the first dose of CUROSURF helped keep FiO2 at lower levels than the first dose of Survanta. The graph below shows how CUROSURF continued to sustain FiO2 levels below the redosing threshold (FiO2 ≥0.30) through the first 48 hours, whereas Survanta did not.3

Chart showing reduction in FiO2 over time vs Survanta
Sustained reduction of FiO2 levels can reduce the need for redosing.3

Adapted from Malloy CA, et al. Acta Paediatr. 2005. (N=58)
*Shading indicates FiO2 range in which redosing was required for infants requiring ventilator support.

Single-dose success in 73% of infants treated with CUROSURF2

The chart below demonstrates the difference in single-dose success between CUROSURF and Survanta in a clinical study.

Chart showing single-dose success vs Survanta
In a clinical trial, more infants experienced RDS success in just one dose when treated with CUROSURF.2

Adapted from Ramanathan R, et al. Am J Perinatol. 2004. (N=293; p<0.002). Results for the 100 mg/kg dose of poractant alfa not reported in the visual.

Sustained results and lower redosing requirements may be attributed to the higher phospholipid concentration of the 200 mg/kg initial dose of CUROSURF. A recent trial compared the 200 mg/kg and 100 mg/kg doses and found that the 200 mg/kg dose of CUROSURF provided a longer disaturated phosphatidylcholine half-life, improved oxygenation, and lower redosing vs the 100 mg/kg dose.4

CUROSURF is indicated for the treatment (rescue) of RDS in premature infants. The FDA-approved initial dose of CUROSURF is 200 mg/kg (2.5 mL/kg). The 100 mg/kg (1.25 mL/kg) dose is approved for repeat dosing only.

Clinical studies have not established that fewer doses, lower volume, or longer dosing intervals result in superior safety or efficacy based on clinically relevant end points.

Next: Less invasive ventilation

Explore how the efficacy of CUROSURF can help you experience fast RDS success by supporting less invasive ventilation strategies.

CUROSURF facilitates efficient administration.
Learn More
Interested in evaluating CUROSURF? Find out how you can smoothly integrate CUROSURF into your NICU by participating in the CUROSURF Experience Program.
Learn More

Indication

CUROSURF® (poractant alfa) Intratracheal Suspension is indicated for the treatment (rescue) of respiratory distress syndrome (RDS) in premature infants. CUROSURF reduces mortality and pneumothoraces associated with RDS.

Important Safety Information

CUROSURF is intended for intratracheal use only. THE ADMINISTRATION OF EXOGENOUS SURFACTANTS, INCLUDING CUROSURF, CAN RAPIDLY AFFECT OXYGENATION AND LUNG COMPLIANCE. Therefore, infants receiving CUROSURF should receive frequent clinical and laboratory assessments so that oxygen and ventilatory support can be modified in response to respiratory changes.

CUROSURF should only be administered by those trained and experienced in the care, resuscitation, and stabilization of preterm infants.

TRANSIENT ADVERSE EFFECTS SEEN WITH THE ADMINISTRATION OF CUROSURF INCLUDE BRADYCARDIA, HYPOTENSION, ENDOTRACHEAL TUBE BLOCKAGE, AND OXYGEN DESATURATION. These events require stopping CUROSURF administration and taking appropriate measures to alleviate the condition. After the patient is stable, dosing may proceed with appropriate monitoring.

Click here for full prescribing information

This site is intended for United States residents only.

Survanta® is a registered trademark of Abbott Laboratories, Inc.

References: 1. Speer CP, Gefeller O, Groneck P, et al. Arch Dis Child. 1995;72:F8-F13. 2. Ramanathan R, Rasmussen MR, Gerstmann DR, Finer N, Sekar K; and The North American Study Group. Am J Perinatol. 2004;21:109-119. 3. Malloy CA, Nicoski P, Muraskas JK. Acta Paediatr. 2005;94:779-784. 4. Cogo PE, Facco M, Simonato M, et al. Pediatrics. 2009;124:e950-e957.